6 articles
Almotriptan
Almotriptan (Almogran, Axert) is an oral 5-HT1B/1D triptan for acute migraine, approved 2001; standard 12.5 mg dose matches sumatriptan 100 mg efficacy with fewer adverse events.
Lasmiditan
Lasmiditan (Reyvow, formerly COL-144/LY573144) is a selective 5-HT1F receptor agonist, the first ditan, FDA-approved 11 October 2019 for acute migraine in adults; non-vasoconstricting, 50-200 mg, one dose per 24 h, 8-hour driving restriction, Schedule V.
Naratriptan
Naratriptan (Amerge) is an oral 5-HT1B/1D receptor agonist triptan for acute migraine in adults, US-approved in 1998; 1 and 2.5 mg doses, 5-6 hour half-life, tolerability similar to placebo.
Rimegepant
Rimegepant (Nurtec ODT, Vydura) is an oral CGRP receptor antagonist (gepant) approved in 2020 for acute migraine treatment in adults and later for episodic migraine prevention, dosed 75 mg orally or every other day.
Ubrogepant
Ubrogepant (Ubrelvy), oral CGRP receptor antagonist (gepant) by Allergan/AbbVie, FDA-approved 2019 for acute migraine with or without aura in adults; 50-100 mg dosing, CYP3A4 interactions, first oral CGRP antagonist approved.
Zolmitriptan
Zolmitriptan (Zomig) is a 5-HT1B/1D agonist triptan for acute migraine in adults, US-approved 1997; tablets, ODT, and nasal spray, 1.25-5 mg doses, max 10 mg/24 h.